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Truncated thioredoxin (Trx-80) promotes pro-inflammatory macro-
phages of the M1 phenotype and enhances atherosclerosis
Dler Mahmood, Amna Abderrazak, Dominique Couchie, Vimala Diderot,
Khadijah El Hadri, Mustapha Rouis
Biological Adaptation and Ageing (B2A), Paris, France
Vascular cells are particularly susceptible to oxidative stress that is
believed to play a key role in the pathogenesis of cardiovascular disorders.
Thioredoxin-1 (Trx-1) is an oxidative stress-limiting protein with anti-inflam-
matory and anti-apoptotic properties. In contrast, its truncated form (Trx-80)
exerts pro-inflammatory effects. Here we analyzed whether Trx-80 might
exert atherogenic effects by promoting macrophage differentiation into the M1
pro-inflammatory phenotype. Trx-80 at 1μg/ml significantly attenuated the
polarization of anti-inflammatory M2 macrophages induced by exposure to
either IL-4 at 15ng/ml or IL-4/IL-13 (10ng/ml each) in vitro, as evidenced by
the expression of the characteristic markers, CD206 and IL-10. By contrast, in
LPS-challenged macrophages, Trx-80 significantly potentiated the differentia-
tion into inflammatory M1 macrophages as indicated by the expression of the
M1 cytokines, TNF-α and MCP-1. When Trx-80 was administered to hyper-
lipoproteinemic ApoE2.Ki mice at 30μg/g body weight (b.w.) challenged
either with LPS at 30μg/30g (b.w.) or IL-4 at 500ng/30g (b.w.), it signifi-
cantly induced the M1 phenotype but inhibited differentiation of M2 macro-
phages in thymus and liver. When ApoE2.Ki mice were challenged once
weekly with LPS for 5 weeks, they showed severe atherosclerotic lesions
enriched with macrophages expressing predominantly M1 over M2 markers.
Such effect was potentiated when mice received daily, in addition to LPS, the
Trx-80. Moreover, the Trx-80 treatment led to a significantly increased aortic
lesion area. The ability of Trx-80 to promote differentiation of macrophages
into the classical proinflammatory phenotype may explain its atherogenic
effects in cardiovascular diseases.
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Role of non-muscular myosin light chain kinase (nmMLCK) in the
inflammation associated with intermittent hypoxia
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Intermittent hypoxia (IH) alters endothelial function favoring inflammation
and could accelerate atherosclerosis-induced cardiovascular diseases. A pro-
tein that may play a role in this process is the non-muscular myosin light chain
kinase (nmMLCK). The deficiency of this kinase protects mice from death in
septic choc models and prevents the atherosclerosis in mice fed with a high fat
dietary. The aim of this study was to analyze the implication of nmMLCK in
the vascular effects and the inflammation induced by IH. Human aortic endo-
thelial cells (HAoECs) and endothelial cells isolated from wild type or defi-
cient nmMLCK mice were exposed to 6h of IH, which include 30min of
hypoxia (O2 5%) followed by 30min of normoxia (O2 21%), in the absence
or the presence of ML-7 (5μM), a nmMLCK inhibitor. After the stimulation,
we evaluated the production of the superoxide anion, nitric oxide (NO), the
pro-inflammatory cytokine IL-6, and also the activation of the NF-κB
pathway. IH treatment increased superoxide, NO and IL-6 production in
HAoECs. However, while the nmMLCK inhibitor ML-7 had no effect on the
IH-induced superoxide anion increase, it decreased both NO and IL-6 produc-
tion. Furthermore, p65-NF-κB pathway was activated by IH in a ML-7-insen-
sitive manner in HAoECs. By using aortic endothelial cells from nmMLCK
deficient mice, we showed that nmMLCK deletion abolished the increase of
superoxide anion induced by IH indicating that the presence and not the kinase
activity of nmMLCK is crucial to regulate oxidative stress induced by IH. In
conclusion, IH induced oxidative and nitrative stresses as well as changes in
inflammatory secretome of human endothelial cells. In this experimental
model of IH, both nitrative and pro-inflammatory cytokine secretion are sen-
sitive to inhibition of the activity of nmMLCK and oxidative stress require its
presence. These results suggest strength the notion that nmMLCK participates
to the IH-induced inflammatory process in endothelial cells.
0289
Inflammation is the main predictor of high-on aspirin platelet reacti-
vity in stable vascular patients treated with monotherapy
Myriam Amsallem (1), Jean Guillaume Dillinger (1), Stéphane Manzo-
Silberman (1), Ludovic Drouet (2), Patrick Henry (1)
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Background: High platelet reactivity (HPR) despite antiplatelet treatment
is related to ischemic events in patients with coronary artery disease (CAD),
but cannot be assessed routinely in all patients. The aim of the study was to
identify clinical and biological predictive factors of HPR on aspirin.
Methods: 333 consecutive patients chronically treated with aspirin for
CAD or cerebrovascular disease with potential high risk of ischemic events
(complex angioplasty, diabetes, recurrence), in whom platelet reactivity was
assessed between 2011 and 2013, were retrospectively analysed. HPR was
evaluated just before the next aspirin intake, defined as aggregation ≥20%
using light transmission aggregometry with arachidonic acid 0.5 mg/mL
(LTA) and closure time <165s using collagen-epinephrine PFA. Adherence
was systematically assessed before sampling.
Results: Median age was 63 years old, 65% were male, with a median
BMI of 25.5 kg/m², 28% had diabetes mellitus and 15% moderate to severe
chronic renal failure. Median dose of aspirin was 100mg/day (range 75 to 160)
and 11% had aspirin twice daily. LTA found HPR in 8.7% patients and PFA
in 20.1%. In a multivariate analysis, predictor factors associated with HPR
using LTA were fibrinogen (OR: 1.51, p=0.01), CRP (OR: 1.01, p<0.01),
vWF level (OR: 1.01, p<0.01) and daily aspirin dose (OR: 0.99, p=0.03).
There was a trend for diabetics to be associated with HPR (OR: 1.19, p=NS)
and for patients with aspirin twice a day to have lower risk of HPR (OR: 0.93,
p=NS). Patients with CRP levels >3.0 mg/mL had a higher rate of HPR
(14.6% versus 2.6%, p<0.01) and a negative predictive value of 97.3% using
LTA. High CRP levels (>3.0mg/mL) were also associated with a 2.6-fold
increased risk of HPR using PFA.
Conclusion: Inflammation is the main predictor of HPR on aspirin in
stable CAD and cerebrovascular patients treated with monotherapy. Further
clinical investigations assessing platelet reactivity should focus on patients
with inflammatory states.
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Background: This study was designed to evaluate the impact of inflamma-
some NLRP3 inhibition by the natural product, arglabin, on inflammatory
response and atherosclerotic lesion in ApoE2Ki mice fed a high fat Western
type diet (HFD).
Methods and results: Arglabin was purified to homogeneity and its chem-
ical identity was confirmed by mass spectrometry. It inhibited IL-1E and IL-
18 production in cultured C57Bl/6, Nlrp3+/+ mouse peritoneal macrophages
in a concentration-dependent manner with a maximum effect at ~50 nM and
EC50 values for both cytokines of ~ 10 nM. In contrast, it has no effect on
both cytokines production in C57Bl/6, Nlrp3-/- cultured peritoneal macro-
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phages. Intraperitoneal injection of arglabin (2.5 ng/g of BW, twice daily,
13 weeks) into female ApoE2Ki mice fed a HFD resulted in a decreased IL-
1E plasma level vs vehicle-treated mice (4.64 ± 1.43 pg/ml vs 11.61 ± 3.05
pg/ml, p<0.01). Surprisingly, arglabin also reduced plasma levels of total cho-
lesterol by ~56% (p<0.01) and triglycerides by ~ 55% (p<0.05). In addition,
arglabin reduced the plasma level of anti-oxLDL antibodies and oriented the
pro-inflammatory M1 macrophages into the anti-inflammatory M2 phenotype
in spleen and arterial lesions. Finally, marked reductions in mean lesion areas
in the sinus (45 ± 19%, p<0.05) and whole aorta (60 ± 2%, p<0.01) were
observed.
Conclusions: Arglabin reduces inflammation, plasma lipids and orients
tissue macrophages into an anti-inflammatory phenotype in ApoE2Ki mice fed
a HFD. Consequently, a marked reduction of atherosclerotic lesions was
observed. Thus, arglabin may represent a new promising drug to treat inflam-
mation and atherosclerosis.
